Search

everythinglearnresearchcommunity

for

Search:↓

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.

JAK inhibitors effectively treat skin conditions and topical forms are safer.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

Compound 1 showed promising anticancer activity.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Blocking mTORC1 reduces skin tumor growth in mice.

Biosimilars lower costs but don't significantly improve access.

Finasteride, a drug used for anti-hyperplasia, can be effectively delivered in the form of matrix tablets.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

IL-9/IL-9R signaling can negatively affect human hair growth and may be a target for treating hair loss conditions.

Polygonum multiflorum may help treat hair loss but can be toxic to the liver.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.

Marine compounds from gorgonians and soft corals show promise for drug development, especially for chronic disorders.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

α-MSH may help treat skin inflammation and fibrosis.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

PDRN may reduce inflammation and complications in revision rhinoplasty for patients with high fibrinogen levels.

Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Blocking YAP/TAZ could be a new way to treat skin cancer.

A new compound shows promise as a topical treatment for hair loss.